GLP-1

News

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

News

France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.

News

Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.

News

Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.

News

For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

News

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.